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ABSTRACT  
Natural selection acts on all organisms, including parasites, to maximise reproductive fitness. Drug 
resistance traits are often associated with life-history costs in the absence of treatment. 
Schistosomiasis control programmes rely on mass drug administration to reduce human morbidity 
and mortality. Although hotspots of reduced drug efficacy have been reported, resistance is not 
widespread. Using Bayesian State-Space Models (SSMs) fitted to data from an in vivo laboratory 
system, we tested the hypothesis that the spread of resistant Schistosoma may be limited by life-
history costs not present in susceptible counterparts. Schistosoma mansoni parasites from a 
praziquantel–susceptible (S), a praziquantel–resistant (R) or a mixed line of originally resistant and 
susceptible parasites (RS) were exposed to a range of praziquantel doses. Parasite numbers at each 
life stage were quantified in their molluscan intermediate and murine definitive hosts across four 
generations, and SSMs were used to estimate key life-history parameters for each experimental 
group over time. Model outputs illustrated that parasite adult survival and fecundity in the murine 
host decreased across all lines, including R, with increasing drug pressure. Trade-offs between adult 
survival and fecundity were observed in all untreated lines, and these remained strong in S with 
praziquantel pressure. In contrast, trade-offs between adult survival and fecundity were lost under 
praziquantel pressure in R. As expected, parasite life-history traits within the molluscan host were 
complex, but trade-offs were demonstrated between parasite establishment and cercarial output. 
The observed trade-offs between generations within hosts, which were modified by praziquantel 
treatment in the R line, could limit the spread of R parasites under praziquantel pressure. Whilst 
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such complex life-history costs may be difficult to detect using standard empirical methods, we 
demonstrate that SSMs provide robust estimates of life history parameters, aiding our 
understanding of costs and trade-offs of resistant parasites within this system and beyond. 
 
KEYWORDS : Schistosoma, praziquantel, drug resistance, fitness costs, establishment, 
survival, reproduction, fecundity, state-space models 
 
INTRODUCTION 
Parasite populations often exhibit considerable genetic variability in their natural tolerance, or 
acquired resistance, to drugs (Pollitt, Sim et al. 2015). Evolutionary theory suggests that one 
potential mechanism for maintaining such diversity, particularly when considering resistance, is 
fitness costs associated with such resistance compared to susceptible lines (Hughes and Andersson 
2015). The existence of life-history costs and trade-offs between them are supported by theoretical 
and empirical studies from both natural and artificial environments across a wide range of organisms 
(Koella and Antia 2003, Koella and Zaghloul 2008, Kempf and Zeitouni 2009, Andersson and Hughes 
2010). However, convincing demonstrations of costs of drug resistance within parasites and 
pathogens, and their underlying causes, have proved elusive, particularly in animal host-parasite 
systems. 
 
Schistosomiasis is a debilitating disease caused by infection with trematode blood flukes. One of the 
main species affecting humans is Schistosoma mansoni, which causes intestinal schistosomiasis 
across sub-Saharan Africa and in pockets of South America and the Middle East (GBD 2016). 
Resistance to praziquantel treatment was first recorded in S. mansoni in the mid-1990s (Ismail, 
Metwally et al. 1996, Ismail, Botros et al. 1999). In 2015, 61 million people were treated during mass 
drug administration (MDA) campaigns, out of the estimated 218 million people across 52 countries 
who require treatment (WHO 2016). Despite this scale of drug pressure and a number of reports 
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suggesting reduced praziquantel efficacy in response to MDA (Danso-Appiah and De Vlas 2002, 
Lawn, Lucas et al. 2003, Cioli, Botros et al. 2004, Black, Steinauer et al. 2009, Melman, Steinauer et 
al. 2009, Wang, Wang et al. 2012, Crellen, Walker et al. 2016), praziquantel resistance still has a 
limited recorded distribution (Botros, Sayed et al. 2005, Wang, Dai et al. 2010, Xu, Xu et al. 2015). 
Whilst observed low cure rates can be caused by a range of factors other than resistance, such as 
high intensities of infection, high rates of reinfection, low drug absorption, and minimal previous 
immunological exposure to schistosomes, cure rates in some areas are lower than expected despite 
taking these factors into consideration (Danso-Appiah and De Vlas 2002).  
 
A range of potential, not mutually exclusive, explanations have been proposed regarding the 
apparent lack of emergence and establishment of praziquantel true resistance to date: i) emergence 
of resistance may be slow due to obligate dioecious sexual reproduction and a diverse complex 
lifecycle (Botros and Bennett 2007); ii) low MDA coverage and untreated lifecycle stages outside of 
the human host provide high levels of refugia for susceptible parasites to persist (King, Muchiri et al. 
2000, Park, Haven et al. 2015); iii) constraining selective pressures from concurrent snail control 
(King, Sutherland et al. 2015, Xu, Xu et al. 2015); or iv) high costs of resistance that limits their 
transmission and fixation capability (William, Sabra et al. 2001, Leathwick 2013). One early 
mathematical model indicated that praziquantel resistance could take over a decade to establish 
due to a combination of these limiting factors (King et al. 2000). Widespread praziquantel resistance 
would undermine the current schistosomiasis control strategies, as there are currently no 
alternative, accessible drug treatments. Therefore, it is important to gather empirical evidence to 
support or refute each of these hypotheses, to inform appropriate interventions at a public health 
level. Such studies also help understand more broadly the complex processes involved in the 
evolution of resistance in multi-host systems. 
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Here, using a laboratory host-parasite system, we explore the hypothesis that there are costs 
associated with resistance which may act to limit the spread of praziquantel resistant parasites. 
Whilst some S. mansoni isolates can maintain resistance in the laboratory without praziquantel 
pressure (Cioli, Botros et al. 2004) other S. mansoni isolates have been reported to revert to 
susceptibility in as few as six mouse passages without treatment (William, Sabra et al. 2001). In the 
absence of drug pressure, praziquantel-resistant S. mansoni lines can have lower cercarial 
production relative to their susceptible counterparts (William, Sabra et al. 2001). However, there are 
inconsistencies across resistant lines, with some lines having lower adult-worm establishment and 
fecundity compared with praziquantel susceptible lines (William, Sabra et al. 2001). Reversion to 
susceptibility and evidence of costs in definitive hosts for some resistant lines provide support that 
life-history costs could act to limit the spread of those resistant lines. However, more experimental 
studies are needed to explicitly measure these differences between lines and how these vary under 
selection pressures.  
 
We combined a snail and mouse laboratory study with statistical modelling to elucidate the life-
history traits, and trade-offs between these traits, across varying doses of in vivo praziquantel in 
drug susceptible, resistant and mixed (50% susceptible and 50% resistant) S. mansoni lines across 
four parasite generations. We test the hypotheses that: i) costs associated with praziquantel 
resistance, displayed within either the intermediate and/or definitive host stage, would reduce the 
overall fitness of the line relative to its susceptible or mixed-selected counterparts in the absence of 
drug pressure, and that net costs would be dependent on both ii) praziquantel dose and iii) selection 
generation. 
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MATERIALS AND METHODS 
Experimental design 
For the selection experiment, full details of the experimental methodology are described in 
Lamberton, Faust et al. (2017). Briefly, there were nine treatment groups in a full factorial design 
with three S. mansoni parasite lines (praziquantel- resistant (R), susceptible, (S) and mixed infection 
(RS: 50% R and 50% S in the first generation) and three praziquantel doses administered to mice 
(control - sham 2% cremophor EL, low- 25mg/kg praziquantel diluted in 2% cremaphor EL, high - 
50mg/kg praziquantel in 2% cremaphor EL). Both doses of praziquantel were sub-curative for all 
parasite lines to ensure long-term maintenance of the line. Parasites from each treatment group 
were maintained for four generations (G1 to G4), using four definitive hosts (female Tuc Ordinary 
(TO) Harlan® adult mice) and 50 indeterminate hosts (30 Biomphalaria glabrata and 20 B. 
alexandrina) in each generation (Fig. 1a and Appendix b Fig. S1).  
 
Observational parasite life-history data 
Mice were exposed to a fixed number of cercariae (220 in G1 and then 110 in G2-G4 due to minor 
mouse morbidity in G1) from the selection line. Six weeks (42 days) post-exposure to cercariae, mice 
were orally gavaged with control, low or high doses of praziquantel. Between 49 and 62 days post 
exposure, mice were euthanized and adult schistosomes counted following collection with a 
modified hepatic perfusion technique (Smithers and Terry 1965). An exception occurred at day 42 in 
G1 when two mice from the low dose R treatment arm became ill and had to be euthanized earlier. 
Counts of adult schistosomes were also collected for these mice. Eggs obtained from the liver and 
spleen of each mouse were washed in saline as described in Lamberton, Faust et al. (2017) and 
placed in direct light in 70ml spring water for one hour to induce hatching of miracidia. Estimates of 
viable miracidia were obtained by counting the number of miracidia in ten 0.2 ml samples per 
mouse.  
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To initiate the asexual stage of the schistosome lifecycle, 50 Biomphalaria snails (30 B. glabrata and 
20 B. alexandrina) per treatment group in 5ml spring water were each exposed to six miracidia that 
were pooled from all mice within the same experimental treatment group. Miracidia remaining after 
two hours of exposure were counted and discarded. Snail survival was recorded weekly. Each week, 
from three weeks post parasite exposure (to allow for maturation of sporocysts and subsequent 
cercarial production (Rollinson and Johnston 1996), snails were placed in the dark for 24 hours and 
then exposed to two hours of light, at 11am, in glass vials containing 16ml spring water, to prompt 
cercarial shedding. The number of cercariae was estimated in two 0.2ml aliquots per snail. Due to 
variation in the number of shedding snails, which may have been influenced by factors external to 
the experimental treatments, cercariae were pooled from ten snails (including any B. alexandrina 
where possible) at ten weeks post-exposure to improve consistency between treatment groups and 
generations. These were then used to infect the next generation of mice. This protocol was 
continued until generation four (G4) (Fig. 1a and Appendix A Fig. S1). Raw data for this experiment 
are shown in Figure 2 (and Appendix B Fig. S2). 
 
Parasite lifecycle state-space model 
To understand the complexities governing potential variation in life-history traits and trade-offs in S. 
mansoni parasite lines, and how these may be impacted by low and high praziquantel doses, we 
modelled the lifecycle of the three lines of S. mansoni across generations. We developed two 
Bayesian stage structured population models implemented within a state-space modelling (SSM) 
framework. The first model emulated the sexual portion of the worm lifecycle inside the definitive 
mouse host. The second model recreates the asexual portion of the lifecycle inside the intermediate 
snail host. Figure 1b illustrates the stages of the worm lifecycle as they were modelled and how each 
stage relates to the experimental data described in Figure 1a. Two independent models were 
implemented as the transition between hosts was experimentally manipulated, i.e. there were not 
natural population dynamics between hosts or generations e.g. each snail was exposed to a fixed 6 
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miracidia (indicated by dotted lines, Fig. 1). We chose a state-space model approach because it 
inherently recognises that the observation process (as determined here by the experimental design, 
sampling, and data collection protocols) is not a direct mirror of the biological process (the parasite’s 
lifecycle) underlying the creation of these observations (e.g. our observations are partial counts of 
the true miracidia/worm/cercariae numbers), and that the reconstruction of this biological process 
requires integration of both these processes (Harvey et al 2004). Furthermore, the ability to use 
priors based on previous studies strengthens our inference. Finally, similar model structures can be 
used for both the sexual and asexual component of the lifecycle, which facilitates interpretations of 
the results across the parasites’ entire lifecycle.  
 
Within-mouse model 
The sexual lifecycle model starts with cercariae (C) establishment inside the mouse. After 
establishment, cercariae develop into adults (A) and the adults that survive can reproduce and lay 
eggs. Once exposed to freshwater, these eggs hatch into miracidia (M). With the within mouse 
model (Fig. 1), we estimate the adult survival (Sa) and fecundity () rates for each parasite line across 
the four generations and the impact of low and high praziquantel doses on these two traits. 
Specifically, we model the number of cercariae in replicate i from generation t, that became 
established inside the mouse and survived to full adult, nA,i,t as a binomial process parameterised by 
the number of cercariae each mouse is exposed to (nA,i,t=220 in t=1 and nA,i,t=110 in t=2,3,4) and 
probability sa,i,t describing the combined establishment and adult survival rate (Fig. 1), which was 
expressed as a logit function of low or high drug dose: 
                                                  (1) 
 
The baseline daily survival of each parasite line (l) 0,l was given a prior distribution derived from a 
beta distribution with mean 0.85 and variance 0.01 (transformed to the logit space, see derivation in 
Appendix C Table S1). The prior is lower than typical daily survival rates to account for low 
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establishment (Smithers 1965) but the variance is wide enough to capture values of 1 or near 0. The 
coefficients 1,l,t and 2,l,t governing the impact of low and high treatment in each parasite line l and 
generation t were estimated using normal distributed priors with mean 0 and precision 0.01, hence 
the impact of praziquantel on survival can be positive or negative. The praziquantel doses were 
modelled as binary switches (i.e. whether a replicate was exposed to high (Highi,t = 1, Lowi,t = 0), low 
(Highi,t = 0, Lowi,t = 1) or no praziquantel (Highi,t = 0, Lowi,t = 0) dose to facilitate computation of these 
separate treatments in each parasite line and generation. Hence, here the adult survival rate is a 
combination of the adult worm survival and the establishment rate of the cercariae inside the 
mouse and the baseline 0,l refers to the survival of control individuals from each line, i.e. those that 
were not exposed to any treatment in any generation. 
 
The adults then reproduce and the number of miracidia (nM0,i,t) emerging per replicate i and 
generation t is estimated as a function of the fecundity rate i,t (Fig. 1), the number of adult worms 
nA,i,t and the adult survival rate sa,i,t: 
                           
   
          (2) 
 
Similar to the survival rate, the fecundity rate i,t was also expressed as a function of praziquantel 
dose: 
                                           (3) 
 
Where 0,l corresponds to the baseline daily fecundity rate of each line and was modelled with a 
normal prior distribution with a mean defined as the average number of eggs laid per day (n=365; 
Loker (1983)) per worm pair, of which 34% mature to miracidia (Chamez 2006) 
(mean=365*0.5*0.34= 62.05), i.e. the fecundity rate is an estimate of the number of eggs laid by one 
unexposed pair of worms, that hatch and become miracidia. The coefficients 1,l,t and 2,l,t governing 
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the impact of low and high treatment were estimated using normal distribution priors with mean 0 
and precision 0.01, and praziquantel doses were again modelled as binary switches. 
 
Because the mice were not all sacrificed at the same time, worms that stayed alive longer during the 
experiment were likely to have laid more eggs during their lifetime. We deal with this potential bias 
in worm counts by weighting the number of adults nA,i,t by a summation of survival sa,i,t across the 
number of days mature reproducing worms were alive in each replicate T, which ranges from T=1, 
i.e. day 42 when the first mouse was culled and miracidia counted to x=20 days, i.e. day 62 when the 
last mouse was culled. This allowed to estimate the cumulative fecundity of worms over their 
mature lifespan in the mouse.  
 
The number of miracidia that survive nM,i,t, was modelled as a binomial process of nM0,i,t and 
probability sm,i,t, describing the miracidia survival rate expressed as a logit function of a parasite line 
specific baseline assuming a prior based on a logit of a beta distribution of mean 0.85 and variance 
0.01. 
       ~   (       ,       )        (4) 
 
Finally, the number of miracidia in the mouse was estimated based on the observed data by 
modelling it as a binomial process of the number of miracidia that survived nM,i,t and the proportion 
p of miracidia in the population that were counted. Given that we have no estimates of the 
proportion of miracidia we can observe, the parameter p was estimated using an uninformative 
uniform prior distribution ranging from 0 to 1. Similarly, the total number of adults observed 
(observational data) is modelled as a binomial process of the number adult that survived nA,i,t and 
the proportion q that are counted. Perfusion techniques enable accurate quantification and 
identification for schistosomes, hence the parameter q was estimated using a beta distribution prior 
with mean 0.9 and variance 0.01.  
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Within-snail model 
The asexual stage of the lifecycle starts with miracidia establishment inside the snail host. Once 
established, the miracidia that survive develop into sporocysts which asexually reproduce and grow 
into cercariae. In the within-snail model, we estimated the miracidia infectivity and cercarial 
shedding rates across the four generations (Fig. 1) and explore the impact of praziquantel dose in 
the previous mouse host on the cercarial shedding rate.  
 
The within-snail model is similar to the within-mouse model. Specifically, the number of miracidia 
which established nMe,i,t inside each snail replicate i from generation t, was modelled as a binomial 
process parametrised with the number of miracidia the mouse was exposed to (n=6) and the 
establishment rate i,t. In turn, i,t is expressed as a logit function of the baseline establishment rate 
of each parasite line and generation using a prior derived from a beta distribution with mean 0.85 
and variance 0.01.  
 
Once established, the average weekly number of cercariae nC0,i,t, emerging per replicate i and 
generation t is estimated as a function of the cercarial shedding rate i,t, and the number of 
miracidia entering into the snail: 
                           (4) 
 
The miracidia develop into and shed cercariae with an average weekly rate i,t, which was modelled 
following equation (3), with the prior for the baseline shedding rate for each line and generation 
derived from a gamma distribution parameterised with mean 200 and variance 1000. The 
coefficients governing the impact of low and high treatment were modelled also from a gamma 
distribution with mean 0.1 and variance 0.01.  
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Finally, the number of cercariae in the snail nC,i,t was estimated based on the observed data by 
modelling it as a binomial process of the number cercariae that survived nC0,i,t and the proportion P 
of observed cercariae, which is estimated using an uninformative uniform prior distribution ranging 
from 0 to 1. Appendix C Table S1 summarises the priors used in both models and provides an 
example of a prior derivation for the logit space. 
 
Model fitting 
The model was fitted using the softwares R and JAGS (Plummer 2003) and two chains were run until 
full convergence was achieved in all parameters, i.e. from 106 iterations run, the first half were 
discarded and every 100th iteration kept for analysis (thinning). Convergence was assessed through 
visual inspection of the trace plots as well as using the Heidelberg diagnostic test. Model 
performance was further assessed through the model fit (i.e. similarity between observations and 
model estimates; see Appendix C Figs. S3, S4 and S5) and congruence between prior and posterior 
distributions (posterior distribution should be narrower but fall within the prior distribution).  
 
RESULTS  
The results of the SSMs were used to address our three hypotheses. Firstly, the differences in the 
life-history traits of the controls (baselines) estimated for each parasite line (S, RS and R) enable 
identification of fitness costs and the net fitness associated with praziquantel resistance. Net fitness 
was estimated within each generation and evaluated as the trade-off between adult worm survival 
and fecundity in the mouse host and miracidia establishment and cercarial production in the snail 
host. Secondly, the comparison of these traits in the control groups with those in the presence of 
low and high doses of praziquantel show how fitness is impacted by praziquantel dose administrated 
to the definitive host. Thirdly, to investigate if there was selection for resistance under drug 
pressure, the individual traits within each line and treatment group were compared cross 
generations. Our parasite lifecycle models provided a good fit to the data observed (Appendix Fig. 
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S2) and converged appropriately, supporting robustness of the model and estimated life-history 
parameters.  
 
i) Life-history traits but not trade-offs differ between parasite lines in control groups. 
In the untreated control groups, the number of observed adult worms, miracidia and cercariae 
differed between parasite lines (Fig. 2). The RS line had the greatest overall fitness with the highest 
number of worms per cercaria, the highest miracidia per adult worm, and highest cercariae per 
miracidium in B. glabrata snails. In the sympatric B. alexandrina snails, however, RS had the lowest 
observed cercarial production. These counts were, nevertheless, variable between generations 
(Appendix A Fig. S2).  
 
In the definitive host, the adult survival rate estimated from the lifecycle model is a combination of 
the adult worm survival and the establishment rate of the cercariae inside the mouse host. The 
average survival of S worms was the most variable across generations, ranging from 0.51 in G3 to 
0.80 worms/cercaria in G4, and was generally lower compared to other lines (Table I, Fig 3a-c x-axis). 
For example, the average survival across generations in S line was 0.65 and in R line was 0.71. RS 
parasites had the most similar rates of adult worm survival between generations, with an average of 
0.77 worms/cercaria (Figure 3b). The estimated fecundity rate for control groups was highly variable 
across our experimental conditions, ranging from 40 (R, G3) to 127 (R, G1) viable 
miracidia/worm/day depending on generation and parasite line (Table I, Fig. 3a-c y-axis). However, 
the fecundity rate of control R worms was generally higher, with a mean across generations of 104 
miracidia/worm/day, compared to 95 and 91 miracidia/worm/day in S and RS lines, respectively. 
Negative trade-offs between survival and fecundity rates were estimated for all control groups 
among all parasites lines, with fecundity decreasing with increasing adult worm survival (Fig. 3a-c 
black line).  
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The results from the intermediate host model (Fig. 3d-i) show that the establishment rates of 
miracidia in the untreated controls was highly variable, but similar among parasite lines and 
between snail host species, ranging between 0.5 and 1 (Fig. 3d-i, x-axis). In contrast, the estimated 
weekly cercarial shedding rates in the untreated control groups differed greatly between the two 
snail species (Fig. 3d-i, y-axis), although no pattern across generation or parasite line was identified. 
The overall cercariae shedding rate was lower and less consistent in B. alexandrina compared with B. 
glabrata (e.g. in RS B. alexandrina ~0-300; B. glabrata ~200-400 cercariae). However, the data 
obtained in B. alexandrina were highly variable across generations and lines, as large numbers of 
snails did not survive once patent, which may have interfered with the estimation of the shedding 
rates. Regardless, in B. alexandrina, our results demonstrated a clear trade-off between 
establishment and shedding rates, where higher establishment rates led to lower cercariae output 
(Fig. 3g-i, black lines). However, these trade-offs were not strong for either R and S lines when 
infecting B. glabrata (Fig. 3d&f black lines).  
 
ii) Praziquantel dose-dependent changes in life-history traits and trade-offs in definitive hosts 
In the definitive host, the observed data from the experiments demonstrated that treatment with 
praziquantel lowers the number of adult worms/cercaria and miracidia/adult worm across the three 
S. mansoni lines (Fig. 2a-b). The data from the snail experiments demonstrated that praziquantel 
treatment in the previous mouse host did not impact the average number of cercariae/miracidium in 
either snail species (Fig. 2c) nor across generations (Appendix B Fig. S2). Our models confirmed these 
observations. Specifically, the within-snail model estimated a negligible impact of praziquantel on 
cercarial production. It is possible that praziquantel impacted cercarial output in some 
line:generation combinations, however, the improved model fit in the absence of these effects, and 
the inconsistency of its magnitude across the replicates, does not provide enough evidence to 
conclude that praziquantel treatment in the mouse host can affect cercarial output in the current 
snail host. Because the effects of praziquantel exposure in the sexual lifecycle stage do not appear to 
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carry through to the asexual lifecycle stage, this suggests that S. mansoni parasites are not impacted 
by indirect exposure to praziquantel. In this section we therefore focus on the impacts of 
praziquantel dose on the sexual life-history parameters of schistosomes in the definitive mouse host.  
 
The results from the within-mouse model suggest that S lines were more impacted, in terms of 
fecundity reduction, by praziquantel than R or RS lines (Fig. 4 compared to Fig 3a-c; Table 1). Indeed, 
fecundity, and to a lesser extent survival, was consistently impacted by 50mg/kg praziquantel 
although with varying magnitudes across generations (Table I). Trade-offs between survival and 
fecundity in S treated lines were similar to control untreated lines, with fecundity decreasing with 
increasing adult worm survival. In R lines, adult survival was most negatively impacted by 50mg/kg 
praziquantel compared to other lines, but fecundity was least affected at the same dosage in nearly 
every generation (Table 1). The net impact of praziquantel on these traits lead to a lack of clear 
trade-offs between fecundity and survival (Fig. 3c,f), suggesting the life-history strategies are 
changed in these R lines even in the presence of low praziquantel doses. Interestingly, in the RS line 
this change in trade-offs only occurs in the presence of the higher 50mg/kg praziquantel dose (Fig. 
4e). This is consistent with its anticipated lower level of resistance compared with the R line, but 
higher level of resistance compared with the S line (Fig 4).  
 
iii) Evidence of selection during the experiment 
Our within-mouse model showed that praziquantel treatment lowered worm density by impacting 
both adult survival and fecundity in all parasite lines (Table 1 and Fig. 4). However, the lack of 
decrease with continued praziquantel dose across generations, suggest that resistance across 
generations was not further selected for. Our within-snail model shows there was positive selection 
for miracidia infectivity in B. glabrata, as seen by the increasing establishment rate of miracidia of all 
lines across generations: from 0.6 in G1 to ~1.0 in G4 (Fig. 3d-f, x-axis). In B. alexandrina the 
establishment rate was low in G1 but was equally high (near 1) in the following three generations.  
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DISCUSSION 
Understanding changes in life-history traits and potential costs of drug resistance in parasites is 
important for managing the emergence of resistance and implementing suitable control measures in 
regions where resistance is found. In this paper, we use state-space models (SSMs) to quantify these 
costs using empirical data from a laboratory study of an indirectly-transmitted parasite. We show 
that it is possible to measure differences in life-history traits in parasite susceptible and resistant 
lines, providing a proof of concept for implementing these techniques in other parasites with 
complex lifecycles. Whilst we observed a large variation in S. mansoni life-history traits between 
praziquantel treated groups and across generations, the parameter estimates generated from the 
model enabled us to show that variation between groups can be better understood when shown as 
life-history trade-offs. Higher fecundity in untreated parasites was associated with lower survival 
within the same generations, meaning that net fitness was similar to untreated parasites in another 
generation that had lower fecundity but higher survival in the definitive host of the same line (Fig. 
5a). However, when adult worms were exposed to praziquantel, trade-offs between fecundity and 
survival in low and high treated R groups and high treated RS groups were no longer observed. This 
suggests that R, and to some extent RS, respond to drug pressure by altering resource allocation, 
affecting observations of life-history trade-offs (Fig. 5b). While this does not explicitly provide 
support for the hypothesis that costs of resistance limit the spread of praziquantel resistant 
phenotypes in natural populations, it does suggest that life-histories are altered in R parasites when 
exposed to praziquantel, but not altered in the S parasite lines. 
 
Using a S. mansoni model, our findings indicate that measuring within host parasite life-history 
trade-offs captures better the complexity of host-parasite interactions which are affected by 
praziquantel, than empirical measures of individual life-history traits. In comparison to classical 
statistical methods (Lamberton, Faust et al. 2017), the SSM was able to differentiate life-history 
traits between parasite lines. This is likely because this SSM method explicitly incorporates the 
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observation process (i.e. experimental design) that generated the data. In contrast to our 
hypothesis, in the absence of praziquantel, R lines did not exhibit a consistent cost compared to S 
lines in either host. Although lower adult survival was observed in R lines, this was accompanied by 
higher fecundity, whilst the negative trade-off between adult worm survival and fecundity was seen 
across all three parasite lines in the absence of praziquantel treatment. In the intermediate host, 
there were also no differences between parasite lines. Life-history traits of other S. mansoni 
praziquantel-resistant lines have been also been shown to be similar to praziquantel-susceptible 
lines in other laboratory studies (e.g. Cioli and Pica-Mattoccia (2003) and others). These findings 
suggest that there are no consistent, observable costs to individual life-history traits measured here 
in the absence of treatment. 
 
However, in the presence of drug treatment, R, and to some extent RS, had altered life-history 
strategies within the definitive host. A negative trade-off between survival and fecundity was less 
apparent in R lines treated with both the low and high praziquantel and RS lines treated with the 
high dose. Trade-offs are less likely to be found when resource availability and/or allocation is 
variable (Noordwijk and de Jong 1986) (Figure 5b). Drug treatment could modify resource allocation 
(Johnson, Boyle et al. 2007), so that R parasites are not only investing energy in survival and 
reproduction. For RS parasites, a negative trade-off between fecundity and survival in adult worms 
was still observed when treated with lower doses of praziquantel (25mg/kg). However, this trade-off 
was altered in the RS line when the higher (50 mg/kg) praziquantel dose was administered, with 
adult worm fecundity barely decreasing at higher adult worm survival. This latter affect appeared to 
be similar to the effect for both praziquantel doses in the R line, indicating a complex interaction 
between drug susceptibility, praziquantel dose, and resource allocation. There was no significant 
difference in adult worm sizes between lines (Lamberton et al. 2017), suggesting that resource 
allocation towards growth could not explain the absence of negative trade-offs under drug pressure. 
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Praziquantel’s exact mechanism of action is unknown, but several studies indicate it may be related 
to calcium (Ca2+) channels and tegument damage (Greenberg 2013). Juvenile worms are not killed 
by praziquantel, it is only after they reach sexual maturity that they are praziquantel susceptible 
(Cioli and Pica-Mattoccia 2003). A study has shown that juvenile worms increase transcription of 
stress response genes that may counteract Ca2+ influx (Hines-Kay et all. 2012), potentially explaining 
their tolerance. If praziquantel induced a similar level of stress in adult worms in R lines, then a 
similar stress response may be predicted. The loss of a trade-off between adult worm survival and 
fecundity in R and RS lines under praziquantel pressure may indicate that R parasites still have the 
ability to increase transcription of stress response genes to protect against praziquantel, and that 
this additional energy sink may cloud trade-offs between fecundity and survival.  
 
Drug pressure has increased dramatically since just 2003 (Webster et al., 2014) but is still currently 
relatively rare in the field, with each person normally treated once a year or less. Therefore, an 
alternative explanation for why resistant parasites have not yet become more widespread is that 
although R parasite lines will be able to establish within a human, their lower overall fecundity make 
it less likely that ‘R’ genes would be transmitted onwards. The existence of such trade-offs could be 
critical to how resistance spreads, particularly given WHO’s recent shift from morbidity control to 
elimination as a public health problem (WHO 2013) and the planned increase in treatment coverage, 
frequency and dose (moving to more communitywide treatment rather than school-aged children, 
twice a year treatments, at potentially a 60mg/kg dose). Further research is required to explore the 
range of trade-off responses and switches to establish if these are related to different expression 
profiles (Greenberg 2013), stress response genes (Hines-Kay et all. 2012) or other genetic or 
epigenetic factors. 
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Previous work has documented lower cercarial production in several resistant lines (William, Sabra 
et al. 2001). Although the R and S parasite lines used have different susceptibilities to praziquantel in 
the definitive mouse host in vivo, definitive host life-history traits were not correlated to traits in the 
intermediate host, with no differences observed between parasite lines or with praziquantel 
treatment. This was consistent with our observation that direct exposure to praziquantel has a 
stronger influence on life-history parameters than parasite line alone, indicating that we may be 
reporting phenotypic or inducible effects, rather than simply genotypic selection. Our model did 
nevertheless support a trade-off between miracidia infectivity and establishment rate with mean 
cercarial shedding, similar to that observed in the definitive host. Establishment increased across the 
experiments, reaching nearly 1.0 in G2 B. alexandrina. The increase in establishment rates in both 
snail species may reflect local adaptation to the particular laboratory strains. Faster adaptation 
within B. alexandrina than in B. glabrata may reflect its role as their natural host even in laboratory 
conditions. Additionally, the larger variation in estimates associated with B. alexandrina may be due 
to a larger genetic variability within the host species compared with the laboratory adapted B. 
glabrata. 
 
In the snail host, there were few differences observed between lines and no effect of indirect 
praziquantel treatment on parasite life-histories. Cercarial production was not different between R 
and S parasite lines, however in early generations of RS, cercarial production was higher than S and 
R individually. Overall, the mixed RS lines also demonstrated the highest establishment and survival 
across all generations, relative to their single line counterparts, supporting previous 
findings(Lamberton, Faust et al. 2017). In a natural system, a mixed infection may be more likely to 
result in increased in fitness, if random mating occurs As Schistosoma species rapidly lose genetic 
variation when passaged in the laboratory (Stohler, Curtis et al. 2004, Gower, Shrivastava et al. 
2007), the increased fitness of RS may be explained by an outbreeding effect, through increased 
genetic diversity, of these two potentially bottlenecked inbred laboratory S and R strains, 
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particularly in the first generation. Some of the variability in the traits measured in these RS lines 
could also be explained by non-random mating and facilitation and/or competition between R and S, 
or a complex combination of all of these. In the trade-off analyses discussed above, survival and 
fecundity trade-offs observed in the co-infected RS line with increased treatment fall between R and 
S lines, correlating with a mid-level of drug resistance.  
 
Although we used subcurative doses of praziquantel (25 mg/kg and 50 mg/kg in a rodent model 
system), this level of treatment may be more relevant to actual MDA campaigns than previously 
thought. We deliberately chose sub-curative doses, to enable us to continue the lifecycle in the 
treated selected lines, as this would not have been possible if all S parasites had died with 
treatment. Cure rates for human treatment are not 100% (Doenhoff, Cioli et al. 2008) and therefore 
our scenario where some worms survive treatment was aimed to be representative of natural 
systems. Indeed, there is recent evidence that under-dosing may be widespread in children due to 
pharmacokinetic differences with adults on whom the drug was initially trialled (Olliaro, Delgado-
Romero et al. 2014, Bustinduy, Waterhouse et al. 2016). As the majority of national treatments are 
administered to children (WHO 2016) modifications to life-history trade-offs seen in our experiment 
may also appear in sub-curative treatments in humans. Declines in fecundity estimated here strongly 
support other empirical studies (Lamberton, Kabatereine et al. 2014), but whether trade-offs 
between fecundity and survival are modified in resistant parasites in natural populations remains an 
open question.  
 
While the experiment was designed to investigate trade-offs that would be nearly impossible to 
observe in the field, there were a few limitations of the design. We saw no differences in definitive 
hosts across generations, but this may be due to the lower sample sizes (n=4) for each treatment 
group per generation, in comparison to the larger sample sizes for snail hosts (n=50 per treatment 
group). In addition, the R and S parasite lines have been passaged in the laboratory for over a 
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decade and may have lost significant genetic diversity. Although, the two strains that were used 
(MOC-S and EE2-R) have significantly different susceptibilities to praziquantel and the levels of 
susceptibility are stable over laboratory passages even in the absence of drug treatment (William, 
Sabra et al. 2001, Sabra and Botros 2008), potential costs may have been reduced under previous 
laboratory selection. In addition, although EE2-R’s stability is important to compare between a 
susceptible and resistant parasite, it might be that the stability is inherently linked to not having high 
costs of resistance. For example, those which lost their resistance rapidly in the laboratory, or could 
not be successfully isolated in the laboratory, may have had higher costs initially, minimising our 
ability to detect them. Our models however, did detect subtle differences in the trade-offs between 
individual traits and how these changed with treatment, particularly in the R lines, which were not 
detected using statistical methods alone (Lamberton, Faust et al. 2017). 
 
Conclusions 
Few empirical data are available on the costs of drug resistance. Here we demonstrate the 
complexity of quantifying costs and the importance of monitoring not just simple trait-specific life-
histories, but within and between host trade-offs. We observed the expected praziquantel dose-
dependent reduction in S. mansoni adult worm survival and establishment in all parasite lines. In 
addition to the survival and fecundity effects, there was evidence of important changes in life-
history trade-offs with praziquantel treatment in R lines. The shape of the trade-off between 
fecundity and survival in R and S adult worms suggested divergent strategies with increasing in vivo 
drug pressure. These results highlight the importance of monitoring multiple life-history traits and 
the trade-offs between them as well as the complexity in interpreting them. Our study also 
highlights the complexity of life-history traits within and between lifecycle stages and experimental 
design, for monitoring evolutionary processes even within a controlled laboratory environment. 
Mass drug administration against schistosomiasis at the current scale and frequency raises concerns 
about the emergence of drug resistance in the parasites (Botros and Bennett 2007, Webster, 
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Molyneux et al. 2014, Bergquist, Utzinger et al. 2017), but such detailed studies would be impossible 
to achieve in the field under natural (human definitive host) conditions. Our results thereby provide 
important insights and have theoretical and applied implications and applications for future 
schistosomiasis control programmes and for other host-parasite-treatment programmes in general. 
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TABLES 
Table 1. SSM estimated key sexual life-history parameters. Median (95% CIs) adult survival and 
fecundity rates baselines (i.e. control groups) and the % reduction over that baseline caused by low 
and high doses of praziquantel in each generation and line.  
 
FIGURES 
Figure 1. Simplified experimental design and lifecycle of S. mansoni (as modelled): A) Each parasite 
line (S, R, and RS) was maintained in the laboratory through passage in four mice and 50 snails in 
each generation for each praziquantel treatment regime. In generation 1 (G1), mice were infected 
with 220 cercariae and in subsequent generations (G2-G4) 110 cercariae were used to infect mice. In 
all generations, six miracidia were used to infect snails. B) The lifecycle of schistosomes was 
modelled using particular life stages. Cercariae (C) enter the definitive mouse host and establish 
themselves as adults (A). Those adults that survive (with survival rate sa) will sexually reproduce and 
lay eggs with a rate , which hatch into miracidia (M). The miracidia that survive (with a rate sm), will 
then leave the mouse host and enter the snail. The miracidia (M) establish inside the intermediate 
snail host with a rate  and will start shedding sporocysts that become cercariae (C) at a rate . A 
new generation will begin as the new cercariae enter the definitive host. The parameters in red 
correspond to those which can be impacted by praziquantel. The dotted arrows indicate steps that 
occurred through experimental manipulation. The schistosome images are modified with permission 
from Genome Research Limited (https://www.yourgenome.org/facts/what-is-schistosomiasis). 
 
Figure 2. Raw data counts of Schistosoma mansoni in the different lifecycle stages for each 
parasite line (symbols: S susceptible; R: resistant; RS: Resistant-susceptible) and praziquantel 
treatment group (colours). Average number (± standard deviation) of a) adult worms per cercaria, b) 
miracidia per adult worm/day; and c) the weekly number of cercariae produced per miracidium 
(right) are estimated across the four generations for each line/treatment group.  
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Figure 3. Untreated control (baseline) life-history traits and trade-offs in the definitive (a-c) and 
intermediate (d-i) hosts. For each Schistosoma mansoni line: susceptible (S; left), mixed resistant 
and susceptible (RS; middle) and resistant (R; right), the median (with 95% CIs) Life-history traits (x- 
and y-axis) are shown for each generation. The trade-offs between traits (black line and associated 
slope, ) were obtained from a Poisson GLM of the posterior distributions of survival (a-c) or 
establishment (d-i) rates against those of fecundity (a-c) or shedding (d-i) rates, respectively. All 
regressions were significant with p<0.001. P-values and standard deviations shown in Appendix C 
Table S2. 
Figure 4. Sexual life-history traits and trade-offs under dose-dependent praziquantel pressure. For 
each Schistosoma mansoni line: susceptible (S; left), mixed resistant and susceptible (RS; middle) and 
resistant (R; right), and praziquantel (PZQ) dose (rows), the median (with 95% CIs) survival (x-axis) 
and fecundity (y-axis) rates are shown for each generation. The trade-offs between these traits 
(black line and associated slope, ) were obtained from a Poisson GLM of the posterior distributions 
of survival and fecundity. All regressions were significant with p<0.001, except R low and R and RS 
high PZQ. P-values and standard deviations shown in Appendix C Table S2. 
Figure 5. Life history traits quantify an organisms’ investment into components of fitness, such 
as reproduction (y-axis) and survivorship (x-axis). A) There are recognised trade-offs between life-
history traits (solid curve), so that an increase in fecundity is associated with decreased survivorship 
(orange) or conversely higher survivorship leads to lower fecundity (green). These life-history trade-
offs arise from limited resources available for an organisms' growth, reproduction and 
survivorship. B) However, trade-off curves can shift as resource (energy) availability for certain traits 
change - this may be due to other resource allocation needs in the organism or a decline in resource 
availability. When this occurs, negative trade-offs are difficult to observe and a decline in one trait 
(orange) may not be compensated by a second observed trait (green). [Figure adapted from work by 
Noordwijk and de Jong 1986] 
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  Susceptible Resistant-Susceptible Resistant 
SURVIVAL     
Baseline 
(control) 
G1 
G2 
G3 
G4 
0.62 (0.59-0.75) 
0.70 (0.62-0.79) 
0.51 (0.40-0.71) 
0.80 (0.74 -0.90) 
0.71 (0.66-0.80) 
0.77 (0.70-0.91) 
0.78 (0.74-0.87) 
0.81 (0.77-0.90) 
0.65 (0.57-0.86) 
0.66 (0.60-0.84) 
0.89 (0.85-0.93) 
0.65 (0.61- 0.74) 
% Reduction 
Low 
praziquantel 
G1 
G2 
G3 
G4 
29.86 (22.7-37.3) 
25.33 (15.4-35.8) 
9.05 (0.0-20.1) 
21.10 (13.4-29.0) 
38.97 (33.0-45.1) 
19.86 (13.1-26.5) 
23.01 (16.9-28.9) 
9.65 (0.0-19.5) 
30.09 (19.1-42.3) 
28.86 (20.2-38.2) 
44.58 (33.5-54.0) 
0 (0-1.1) 
% Reduction 
High 
praziquantel 
G1 
G2 
G3 
G4 
53.24 (44.0-59.3) 
30.63 (17.6-39.7) 
8.17 (0.0-19.7) 
12.54 (2.3-23.0) 
8.88 (0.4-17.5) 
31.74 (23.2-39.4) 
22.69 (16.1-29.7) 
19.43 (12.6-25.2) 
52.39 (42.2-59.3) 
48.84 (37.5-57.6) 
49.19 (42.1-55.7) 
40.48 (32.5-47.7) 
FECUNDITY     
Baseline 
(control) 
G1 
G2 
G3 
G4 
123 (105-141) 
65 (53-81) 
115 (94-136) 
77 (69-86) 
117 (101-134) 
89 (70-111) 
75 (55-98) 
85 (70-108) 
127 (114-141) 
120 (107-140) 
40 (33-54) 
129 (110-149) 
% Reduction 
Low 
praziquantel 
G1 
G2 
G3 
G4 
27.69 (17.97-36.81) 
0.0 (0.0-8.59) 
0.0 (0.0-5.99) 
31.02 (13.81-46.57) 
0.0 (0.0-0.0) 
2.97 (0.0-17.05) 
0.0 (0.0-0.0) 
40.76 (27.74-53.53) 
0.0 (0.0-5.38) 
4.34 (0.0-16.20) 
0.0 (0.0-0.0) 
0.0 (0.0-8.41) 
% Reduction 
High 
praziquantel 
G1 
G2 
G3 
G4 
4.98 (0.0-14.11) 
44.21 (26.83-58.00) 
3.78 (0.0-17.11) 
71.07 (60.65-76.95) 
42.30 (31.13-50.78) 
21.79 (2.46-36.21) 
21.35 (9.84-34.56) 
17.06 (1.59-35.31) 
14.58 (2.28-23.03) 
10.56 (0.0-19.11) 
37.29 (24.45 50.80) 
14.30 (1.8024.93) 
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